Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) Director Jeffrey S. Glenn purchased 15,460 shares of the company’s stock in a transaction on Friday, November 18th. The shares were purchased at an average price of $12.74 per share, with a total value of $196,960.40. Following the completion of the purchase, the director now directly owns 16,355 shares of the company’s stock, valued at $208,362.70. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) opened at 12.95 on Wednesday. The stock’s market cap is $108.21 million. The stock has a 50 day moving average price of $12.46 and a 200 day moving average price of $16.71. Eiger BioPharmaceuticals Inc. has a 12 month low of $10.71 and a 12 month high of $28.35.

Several brokerages have commented on EIGR. Zacks Investment Research lowered Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 10th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $34.00 price target on shares of Eiger BioPharmaceuticals in a research note on Monday. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Eiger BioPharmaceuticals in a research note on Thursday, August 11th. Finally, Jefferies Group restated a “buy” rating and set a $33.00 price target on shares of Eiger BioPharmaceuticals in a research note on Thursday, October 20th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $34.00.

Several large investors have recently added to or reduced their stakes in the company. Teachers Advisors Inc. bought a new stake in Eiger BioPharmaceuticals during the second quarter valued at $108,000. California State Teachers Retirement System bought a new stake in Eiger BioPharmaceuticals during the second quarter valued at $144,000. Bank of New York Mellon Corp bought a new stake in Eiger BioPharmaceuticals during the second quarter valued at $214,000. BlackRock Investment Management LLC raised its stake in Eiger BioPharmaceuticals by 4,942.9% in the second quarter. BlackRock Investment Management LLC now owns 12,355 shares of the company’s stock valued at $245,000 after buying an additional 12,110 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new stake in Eiger BioPharmaceuticals during the third quarter valued at $169,000. 39.95% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Jeffrey S. Glenn Purchases 15,460 Shares of Eiger BioPharmaceuticals Inc. (EIGR) Stock” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/23/jeffrey-s-glenn-purchases-15460-shares-of-eiger-biopharmaceuticals-inc-eigr-stock.html.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

5 Day Chart for NASDAQ:EIGR

Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.